- Correction
- Open access
- Published:
Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors
Journal of Experimental & Clinical Cancer Research volume 42, Article number: 102 (2023)
The Original Article was published on 29 March 2023
Correction: J Exp Clin Cancer Res 42, 76 (2023)
https://doi.org/10.1186/s13046-023-02649-6
Following publication of the original article [1], an error was identified in Fig. 2, specifically:
-
Fig. 2b - CL/F (mL/hr) needs to be corrected in CL/F (L/hr)
Furthermore, two Supplementary Materials should also be uploaded. The added Supplementary Materials are:
-
Additional file 7: Supplementary Materials and Methods.
-
Additional file 8: NEO-201 protocol.
This modification does not affect the integrity of the results.
Clinical Pharmacokinetics of NEO-201 A. NEO-201 serum concentrations averaged for each dose level and plotted over time. B. Noncompartmental analysis of first dose of NEO-201 including the mean estimates for relevant PK parameters during dense PK sampling following the first dose given on C1D1. *Data presented as arithmetic means (%CV) due to low numbers in each group. 1 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 2 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 3 Four patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 4 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 5 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. C. Individual NEO-201 serum concentration–time profiles of 1.0 mg/kg cohort. D-E. Individual NEO-201 serum concentration–time profiles of patients in 1.5 mg/kg cohort (D) and 2.0 mg/kg cohort (E). F-G. Differences in NEO-201 distribution volume by sex (F) and body size (G)
References
Cole CB, Morelli MP, Fantini M, et al. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. J Exp Clin Cancer Res. 2023;42:76. https://doi.org/10.1186/s13046-023-02649-6.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The online version of the original article can be found at https://doi.org/10.1186/s13046-023-02649-6.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Cole, C.B., Morelli, M.P., Fantini, M. et al. Correction: First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. J Exp Clin Cancer Res 42, 102 (2023). https://doi.org/10.1186/s13046-023-02668-3
Published:
DOI: https://doi.org/10.1186/s13046-023-02668-3